Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways

Despite the implementation of multiple HER2-targeted therapies, patients with advanced HER2(+) breast cancer ultimately develop drug resistance. Stromal fibroblasts represent an abundant cell type in the tumor microenvironment and have been linked to poor outcomes and drug resistance. Here, we show...

Descripción completa

Detalles Bibliográficos
Autores principales: Zervantonakis, Ioannis K., Poskus, Matthew D., Scott, Alexis L., Selfors, Laura M., Lin, Jia-Ren, Dillon, Deborah A., Pathania, Shailja, Sorger, Peter K., Mills, Gordon B., Brugge, Joan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2020
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368275/
https://www.ncbi.nlm.nih.gov/pubmed/32601199
http://dx.doi.org/10.1073/pnas.2000648117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368275/
https://www.ncbi.nlm.nih.gov/pubmed/32601199
http://dx.doi.org/10.1073/pnas.2000648117

Ejemplares similares